Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-308: Subcutaneous Tarlatamab in Extensive Stage Small Cell Lung Cancer
NCT06598306Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 10
01
Overview
Phase 1, open-label trial of tarlatamab in small cell lung cancer (SCLC) (3 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent Adverse Events and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06598306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598306.